- Home
- MIRM vs WERN Comparison
MIRM vs WERN Comparison
Compare MIRM & WERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- WERN
- Stock Information
- Founded
- MIRM 2018
- WERN 1956
- Country
- MIRM United States
- WERN United States
- Employees
- MIRM N/A
- WERN N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- WERN Trucking Freight/Courier Services
- Sector
- MIRM Health Care
- WERN Industrials
- Exchange
- MIRM Nasdaq
- WERN Nasdaq
- Market Cap
- MIRM 1.9B
- WERN 1.8B
- IPO Year
- MIRM 2019
- WERN N/A
- Fundamental
- Price
- MIRM $44.27
- WERN $26.22
- Analyst Decision
- MIRM Strong Buy
- WERN Hold
- Analyst Count
- MIRM 10
- WERN 12
- Target Price
- MIRM $60.80
- WERN $30.33
- AVG Volume (30 Days)
- MIRM 425.9K
- WERN 1.1M
- Earning Date
- MIRM 05-07-2025
- WERN 04-29-2025
- Dividend Yield
- MIRM N/A
- WERN 2.14%
- EPS Growth
- MIRM N/A
- WERN N/A
- EPS
- MIRM N/A
- WERN 0.29
- Revenue
- MIRM $379,251,000.00
- WERN $2,973,292,000.00
- Revenue This Year
- MIRM $29.51
- WERN $3.79
- Revenue Next Year
- MIRM $20.27
- WERN $7.03
- P/E Ratio
- MIRM N/A
- WERN $91.93
- Revenue Growth
- MIRM 69.31
- WERN N/A
- 52 Week Low
- MIRM $23.83
- WERN $23.02
- 52 Week High
- MIRM $54.23
- WERN $42.48
- Technical
- Relative Strength Index (RSI)
- MIRM 56.45
- WERN 43.07
- Support Level
- MIRM $40.00
- WERN $25.01
- Resistance Level
- MIRM $47.43
- WERN $26.38
- Average True Range (ATR)
- MIRM 2.07
- WERN 0.96
- MACD
- MIRM 0.54
- WERN 0.01
- Stochastic Oscillator
- MIRM 65.27
- WERN 48.12
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.